Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease

Alexis Arasu¹, Niyati Sharma², Anousha Yazdabadi^{3

4}, Michael Sladden⁵

Affiliations

¹ Alfred Health, Melbourne, Victoria, Australia.
² Department of Dermatology, Monash Health, Clayton, Victoria, Australia.
³ Department of Dermatology, Eastern Health, Box Hill, Victoria, Australia.
⁴ Department of Medical Education, University of Melbourne, Melbourne, Victoria, Australia.
⁵ Department of Medicine, University of Tasmania, Launceston, Tasmania, Australia.

Alexis Arasu et al. Australas J Dermatol. 2022 Feb.

. 2022 Feb;63(1):110-111.

doi: 10.1111/ajd.13743. Epub 2021 Nov 10.

Alexis Arasu¹, Niyati Sharma², Anousha Yazdabadi^{3

4}, Michael Sladden⁵

¹ Alfred Health, Melbourne, Victoria, Australia.
² Department of Dermatology, Monash Health, Clayton, Victoria, Australia.
³ Department of Dermatology, Eastern Health, Box Hill, Victoria, Australia.
⁴ Department of Medical Education, University of Melbourne, Melbourne, Victoria, Australia.
⁵ Department of Medicine, University of Tasmania, Launceston, Tasmania, Australia.

No abstract available

References

1. Ravnborg N, Ambikaibalan D, Agnihotri G et al. Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2021; 84: 471-8.
1. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy. Clin. Immunol. 2001; 108: 184-90.
1. Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-303.
1. Fougerousse AC, Becherel PA, Pallure V et al. Combining omalizumab with another biotherapy. Acta. Derm. Venereol. 2019; 99: 448-9.
1. Ghazanfar MN, Thomsen SF. Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis. J. Dermatolog. Treat. 2019; 30: 387-8.